Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis
Abstract Background As disease-modifying therapies do not reverse the course of multiple sclerosis (MS), assessment of therapeutic success involves documenting patient-reported outcomes (PROs) concerning health-related quality of life, disease and treatment-related symptoms, and the impact of sympto...
Main Authors: | Nupur Greene, Stéphane Quéré, Denise P. Bury, Flora Mazerolle, Manal M’Hari, Angély Loubert, Antoine Regnault, Keiko Higuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-07-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-023-00594-8 |
Similar Items
-
Identification of Key Ferroptosis-Related Genes in the Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis and Its Diagnostic Value
by: Xi Song, et al.
Published: (2023-03-01) -
Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01) -
Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
by: Lita Araujo, et al.
Published: (2022-11-01) -
A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study
by: Arpit Agrawal, et al.
Published: (2023-08-01) -
Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)